Group 1 - Wangshan Wangshui-B (02630) surged over 14%, reaching a new high, following the announcement of significant antiviral research against Nipah virus by a team including researchers from the Wuhan Institute of Virology and Shanghai Institute of Materia Medica [1] - Zhaoyi Innovation (03986) increased by over 5.6%, with a forecasted revenue of approximately 9.2 billion yuan for 2025, representing a year-on-year growth of about 25%, and a projected net profit of around 1.61 billion yuan, up 46% [1] - Youran Dairy (09858) rose over 4% after completing a placement of 299.25 million shares at a price of 3.92 HKD per share [1] Group 2 - Yijun Group Holdings (02442) experienced a decline of over 39%, despite a previous surge of 4.4 times since its relisting on December 3, 2022 [2] - Alibaba-W (09988) saw a rise of 1.82% after the launch of its Qwen3-Max-Thinking model, which has over 1 trillion parameters and 36 trillion tokens of pre-training data [2][3] - Junda Co., Ltd. (02865) fell nearly 11%, with a drop of over 30% from its recent peak, following an announcement of a strategic investment in Shanghai Xingyi Xinneng Technology Co., Ltd. [2] Group 3 - WanGuo Data-SW (09698) increased by over 6%, also in response to the launch of Alibaba's Qwen3-Max-Thinking model [3] - MicroPort Scientific Corporation-B (02160) dropped 11% after announcing a proposed share consolidation [3] - Valiant Pharmaceuticals-B (09887) rose nearly 4% after receiving orphan drug designation from the European Commission for its core product [4] Group 4 - AI application software stocks in the US saw significant gains, with Cloudflare (NET.US) up 9.17% and Zoom Communications (ZM.US) up 11.28% [5] - Apple (AAPL.US) rose 2.97% ahead of its Q1 2026 earnings report, with expected revenue growth of 11.3% year-on-year to 138.42 billion USD [5] - Intel (INTC.US) continued its decline, falling 5.72% after a previous drop, with revenue expectations for Q1 2026 significantly below market forecasts [5] Group 5 - Kingsoft Cloud (KC.US) increased by 8.1% following a strategic upgrade of its AI training and deployment platform [6] - Precious metals stocks saw pre-market gains, with First Majestic Silver (AG.US) up 1.1% as gold prices reached historical highs [6]

责任编辑：卢昱君 1月26日盘后，中国科学院武汉病毒研究所微信公众号发文称，近期，中国科学院武汉病毒研究所肖庚 富/张磊砢研究员团队、单超研究员团队联合上海药物研究所、旺山旺水生物医药股份有限公司胡天文 博士在国际期刊发表的重要研究成果，证实口服核苷类药物VV116对尼帕病毒具有显著的抗病毒活性， 为这一高致死性新发传染病的防治带来新希望。该成果首次证实VV116对尼帕病毒的治疗潜力，不仅可 作为医护人员、实验室工作者等高危人群的预防性用药，更可为应对当下和未来的尼帕病毒疫情提供了 一个现成的药物选择。 公开资料显示，旺山旺水成立于2013年，重点布局神经精神、生殖健康和病毒感染三大治疗领域。去年 12月，旺山旺水宣布与先声药业签订许可和合作协议。 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 旺山旺水-B（02630）早盘一度涨超14%，高见112.70港元，创上市新高。截至发稿，股价上涨 10.59%，现报108.60港元，成交额2641.54万港元。 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 旺山旺水-B（02630）早盘一度涨超14%，高见112.70港元， ...

Core Insights - The emergence of Nipah virus cases in West Bengal, India, with a mortality rate exceeding 40%, has raised significant concerns [1] - The research published by the Wuhan Institute of Virology indicates that the oral nucleoside drug VV116 shows promising antiviral activity against Nipah virus, providing new hope for treatment [1][2] Group 1: Drug Development - VV116 is a novel oral nucleoside antiviral drug that has been approved for COVID-19 treatment in Uzbekistan and China [3] - In vitro studies demonstrate that VV116 and its active metabolites significantly inhibit Nipah virus, including Malaysian strain NiV-M and Bangladeshi strain NiV-B [3] - In a lethal dose infection model in golden hamsters, VV116 at a dosage of 400 mg/kg increased survival rates to 66.7% and significantly reduced viral loads in target organs such as the lungs, spleen, and brain [3] Group 2: Market Reaction - Following the announcement of VV116's potential against Nipah virus, the stock of its parent company, Wangshan Wangshui (02630.HK), surged over 10% on January 27 [4] - Despite the positive market reaction, VV116 is still in the preclinical research stage and requires human clinical trials, regulatory approval, and market launch before it can be used as a treatment [4] Group 3: Historical Context - Nipah virus is not a new virus, having caused outbreaks in Malaysia, Singapore, India, and Bangladesh since 1998 [4] - The lack of effective vaccines and therapies for Nipah virus over the years is attributed to insufficient funding for research and relatively low case numbers, despite its high mortality rate [4]

消息面上，近日，印度西孟加拉邦暴发尼帕病毒疫情。可人传人，死亡率最高达75%，尚无疫苗。近期，中国科学院武汉病 毒研究所肖庚富/张磊砢研究员团队、单超研究员团队联合上海药物研究所、旺山旺水生物医药股份有限公司胡天文博士在 国际期刊Emerging Microbes & Infections上发表题为"The oral nucleoside drug VV116 is a promising candidate for treating Nipah virus infection"的重要研究成果，证实口服核苷类药物VV116对尼帕病毒具有显著的抗病毒活性，为这一高致死性新发传染 病的防治带来新希望。该成果首次证实VV116对尼帕病毒的治疗潜力，不仅可作为医护人员、实验室工作者等高危人群的 预防性用药，更可为应对当下和未来的尼帕病毒疫情提供了一个现成的药物选择。 1月27日，旺山旺水-B(2630.HK)盘中拉升涨近15%报112.7港元，股价创历史新高，市值升至逾189亿港元。 港股频道更多独家策划、专家专栏，免费查阅>> 责任编辑：栎树 据悉，口服核苷类药物VV116由中科院上海药物研究所、上海君实生物等单位 ...

每经AI快讯，旺山旺水-B(02630.HK)一度涨超14%，截至发稿，涨12.02%，报110港元，成交额1292.81 万港元。 ...

旺山旺水-B(2630.HK)盘中拉升涨近15%报112.7港元，股价创历史新高，市值升至逾189亿港元。 本文源自：金融界AI电报 ...

旺山旺水-B(02630)一度涨超14%，高见112.7港元创上市新高。截至发稿，涨12.02%，报110港元，成交 额1292.81万港元。 公开资料显示，旺山旺水成立于2013年，重点布局神经精神、生殖健康和病毒感染三大治疗领域。去年 12月，旺山旺水宣布与先声药业签订许可和合作协议。依据该协议，旺山旺水将授予先声药业VV116呼 吸道合胞病毒（RSV）感染适应症和人偏肺病毒（HMPV）感染适应症在大中华区（包括中国大陆、香 港特别行政区、澳门特别行政区及台湾地区）的独家开发、制造及商业化权利。 消息面上，1月26日盘后，中国科学院武汉病毒研究所微信公众号发文称，近期，中国科学院武汉病毒 研究所肖庚富/张磊砢研究员团队、单超研究员团队联合上海药物研究所、旺山旺水生物医药股份有限 公司胡天文博士在国际期刊发表的重要研究成果，证实口服核苷类药物VV116对尼帕病毒具有显著的抗 病毒活性，为这一高致死性新发传染病的防治带来新希望。该成果首次证实VV116对尼帕病毒的治疗潜 力，不仅可作为医护人员、实验室工作者等高危人群的预防性用药，更可为应对当下和未来的尼帕病毒 疫情提供了一个现成的药物选择。 ...

据悉，口服核苷类药物VV116由中科院上海药物研究所、上海君实生物等单位联合研发，由上海旺实生物医药科技有限公司持有，由上海迪赛诺生物医 药有限公司作受托生产。旺实生物是君实生物控股子公司上海君拓生物医药科技有限公司与苏州旺山旺水生物医药有限公司联合控股的子公司。 旺山旺水-B(2630.HK)盘中拉升涨近15%报112.7港元，股价创历史新高，市值升至逾189亿港元。 消息面上，近日，印度西孟加拉邦暴发尼帕病毒疫情。可人传人，死亡率最高达75%，尚无疫苗。近期，中国科学院武汉病毒研究所肖庚富/张磊砢研究 员团队、单超研究员团队联合上海药物研究所、旺山旺水生物医药股份有限公司胡天文博士在国际期刊Emerging Microbes & Infections上发表题为"The oral nucleoside drug VV116 is a promising candidate for treating Nipah virus infection"的重要研究成果，证实口服核苷类药物VV116对尼帕病毒具有显著的抗 病毒活性，为这一高致死性新发传染病的防治带来新希望。该成果首次证实VV116对尼帕病毒的治疗潜力，不 ...

Core Viewpoint - The stock of Wangshan Wangshui-B (02630) surged over 14%, reaching a new high of 112.7 HKD, following the announcement of significant research findings regarding the antiviral drug VV116 against Nipah virus [1] Company Summary - Wangshan Wangshui was established in 2013, focusing on three therapeutic areas: neuropsychiatry, reproductive health, and viral infections [1] - The company announced a licensing and collaboration agreement with Ascletis Pharma in December, granting exclusive rights for the development, manufacturing, and commercialization of VV116 for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) infections in Greater China [1] Industry Summary - Recent research published by the Wuhan Institute of Virology confirmed that the oral nucleoside drug VV116 has significant antiviral activity against the Nipah virus, providing new hope for the prevention and treatment of this highly fatal emerging infectious disease [1] - The findings suggest that VV116 could serve as a preventive medication for high-risk groups such as healthcare workers and laboratory personnel, as well as a ready drug option for current and future Nipah virus outbreaks [1]

格隆汇1月21日丨ST华西（维权）(002630.SZ)公布，公司于2026年1月21日召开第六届董事会第二十一 次会议, 通过了《关于聘任公司董事会秘书的议案》。经公司董事长提名，董事会提名委员会任职资格 审查通过，公司董事会同意聘任吴胜峰为公司董事会秘书，任期从本次董事会审议通过之日起至第六届 董事会任期届满。公司董事长黄有全先生不再代行董事会秘书职责。 ...